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Background: In patients with nonvalvular atrial fibrillation, the nidus for thromboembolic stroke is predominantly the left atrial appendage (LAA). 
The PROTECT AF trial evaluated whether LAA closure would produce outcomes similar to warfarin (WARF) without the need for anticoagulation. Initial 
data documented non-inferiority of LAA closure; this analysis compared outcome of PROTECT AF patients (pts) at 1200 patient years (p-y) with the 
initial 600 p-y data.
Methods: Patients were randomized to either implant plus WARF for 45 days (463 pts) or WARF alone indefinitely (244 pts). Primary efficacy 
endpoint included all stroke, CV or unexplained death, and systemic embolization. Primary safety endpoint included device embolization, pericardial 
effusion, and major or intracranial bleeding.
Results: At average follow-up of 11 ± 9 and 21 ± 11 months, results were: 
Outcome Analysis Cohort
Device Rate/100
p-y
(95% CI)
Warfarin Rate/100
p-y
(95% CI)
Relative
Risk
Primary Efficacy 600 p-y
4.4
(2.6, 6.7)
5.8
(3.0, 9.1)
0.76
(0.39, 1.67)
1200 p-y
3.2
(2.1, 4.6)
4.5
(2.6, 6.5)
0.70
(0.41, 1.39)
Primary Safety 600 p-y
11.6
(8.5, 15.3)
4.1
(1.9, 7.2)
2.85
(1.48, 6.43)
1200 p-y
6.5
(4.8, 8.5)
4.1
(2.4, 6.2)
1.59
(0.95, 2.92)
All-cause Mortality 600 p-y
3.4
(1.8, 5.4)
4.9
(2.3, 7.8)
0.69
(0.33, 1.66)
1200 p-y
2.8
(1.9, 4.2)
4.7
(2.7, 6.6)
0.61
(0.36, 1.22)
Compared to the 600 p-y analysis, by 1200 p-y the relative risk of primary efficacy events and all-cause mortality showed continued decrease with 
device implantation compared with WARF (device event rates decreasing by approximately 30%) and narrower confidence intervals supporting the 
non-inferiority finding. Primary safety events declined by over 40% with device while adverse events related to WARF continued, with a corresponding 
decrease of 44% in relative risk associated with device placement.
Conclusion: Long term trends indicate improved risk-benefit profile for device LAA closure compared with warfarin.
